Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter earnings report, alongside results from a closely watched trial of its ...

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, ...

In the latest trading session, Novo Nordisk (NVO) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a ...